Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice by Taylor, M. et al.
Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 
knockout mice 
M. S. Sidorov, D. D. Krueger, M. Taylor, E. Gisin, E. K. Osterweil and M. F. Bear 
Abstract 
Fragile X (FX) is the most common genetic cause of intellectual disability and autism. 
Previous studies have shown that partial inhibition of metabotropic glutamate receptor 
signaling is sufficient to correct behavioral phenotypes in a mouse model of FX, 
including audiogenic seizures, open-field hyperactivity and social behavior. These 
phenotypes model well the epilepsy (15%), hyperactivity (20%) and autism (30%) that 
are comorbid with FX in human patients. Identifying reliable and robust mouse 
phenotypes to model cognitive impairments is critical considering the 90% comorbidity 
of FX and intellectual disability. Recent work characterized a five-choice visuospatial 
discrimination assay testing cognitive flexibility, in which FX model mice show 
impairments associated with decreases in synaptic proteins in prefrontal cortex (PFC). In 
this study, we sought to determine whether instrumental extinction, another process 
requiring PFC, is altered in FX model mice, and whether downregulation of metabotropic 
glutamate receptor signaling pathways is sufficient to correct both visuospatial 
discrimination and extinction phenotypes. We report that instrumental extinction is 
consistently exaggerated in FX model mice. However, neither the extinction phenotype 
nor the visuospatial discrimination phenotype is corrected by approaches targeting 
metabotropic glutamate receptor signaling. This work describes a novel behavioral 
extinction assay to model impaired cognition in mouse models of neurodevelopmental 
disorders, provides evidence that extinction is exaggerated in the FX mouse model and 
suggests possible limitations of metabotropic glutamate receptor-based pharmacotherapy. 
Introduction 
Fragile X (FX) syndrome, the leading inherited cause of intellectual disability and autism, 
is caused by transcriptional silencing of the FMR1 gene and loss of the gene product, 
fragile X mental retardation protein (FMRP; Verkerk et al. 1991). The Fmr1 knockout 
(KO) mouse (The Dutch-Belgian Fragile X Consortium 1994) lacks FMRP, a 
translational repressor (Laggerbauer et al. 2001; Li et al. 2001), resulting in increased 
protein synthesis (Qin et al. 2005), and has well-characterized behavioral deficits 
consistent with the presentation of FX in humans. Specifically, FX has high comorbidity 
with epilepsy (∼15%), hyperactivity (∼20%) and autism (∼30 – 60%) (Schneider et al. 
2009). Consistent with these clinical findings, Fmr1 KO mice show increased seizure 
susceptibility (Yan et al. 2004), open-field activity (The Dutch-Belgian Fragile X 
Consortium 1994; Mineur et al. 2002) and social deficits (Oddi et al. 2013). Cognitive 
impairments in Fmr1 KO mice have been comparatively understudied, considering the 
∼90% comorbidity between FX and intellectual disability (Schneider et al. 2009). Fmr1 
KO mice show learning deficits in multiple contexts, such as spatial and procedural 
learning, inhibitory avoidance and sustained attention (D’hooge et al. 1997; Dolen et al. 
2007; Koekkoek et al. 2005; Kramvis et al. 2013; Michalon et al. 2012; Moon et al. 2006; 
Vinueza Veloz et al. 2012). However, apart from conflicting reports of attentional 
dysfunction (Kramvis et al. 2013; Krueger et al. 2011; Moon et al. 2006), the majority of 
learning tests in Fmr1 KO mice are not sufficient to model cognitive dysfunction 
mediated by prefrontal cortex (PFC). 
Fmr1 KO mice show impairments in a visuospatial discrimination task which are 
consistent with deficits in cognitive flexibility, and this impairment is linked to altered 
synaptic protein levels in PFC (Krueger et al. 2011). Extinction of operant behaviors is 
also an active cognitive process (Bouton 2002) and relies on top-down control of PFC, 
independent of the nature of the reinforcer (Cleva et al. 2010; Millan et al. 2011; Rebec & 
Sun 2005). Substantial evidence suggests that metabotropic glutamate receptor 5 (mGlu5) 
is involved in regulating PFC-mediated operant extinction (Chesworth et al. 2013; Cleva 
et al. 2011; Gass & Olive 2009; Kufahl et al. 2012), and extinction of hippocampally 
encoded inhibitory avoidance is altered in Fmr1 KO mice (Dolen et al. 2007). As mGlu5-
mediated processes are involved in FX pathogenesis (Bear et al. 2004), we were thus 
motivated to study instrumental extinction in Fmr1 KO mice. 
Enhanced synaptic protein synthesis in FX is likely to be pathogenic, and 
pharmacological approaches to downregulate protein synthesis are currently being 
evaluated in clinical trials based on their success in Fmr1 KO mice (Krueger & Bear 
2011). Metabotropic glutamate receptor 5 signaling is positively coupled to translation 
through an extracellular signal-regulated kinase (ERK1/2) signaling pathway (Osterweil 
et al. 2010), and modest downregulation of mGlu5 or ERK1/2 signaling is sufficient to 
normalize protein synthesis and behavior in Fmr1 KO mice (Dolen et al. 2007; Michalon 
et al. 2012, 2013; Osterweil et al. 2013; Yan et al. 2005). We sought to determine 
whether downregulation of these signaling pathways could also correct altered 
visuospatial discrimination and instrumental extinction in Fmr1 KO mice. 
Materials and methods 
Subjects 
Fmr1 KO mice (The Dutch-Belgian Fragile X Consortium 1994) and Grm5+/− mice (Lu 
et al. 1997) were obtained from Jackson Labs (Bar Harbor, ME, USA) (stock nos 3558 
and 3025, respectively). Both strains were backcrossed onto a C57BL/6J background for 
at least six generations at MIT and were subsequently maintained on a congenic 
C57BL/6J background by regular additional backcrosses. Mice were group housed with 
littermates and maintained on a 1200:1200h light:dark cycle. Experimental cohorts 
consisted of male littermates that were aged 2 – 4 months at the time of experiments. 
Cohorts were obtained from wild-type (WT) male × Fmr1 heterozygous female breeders 
(for experiments involving only Fmr1 WT and Fmr1 KO groups as well as for 
experiments involving Fmr1 WT/vehicle, Fmr1 WT/lova, Fmr1 KO/vehicle and Fmr1 
KO/lova groups) or Grm5 heterozygous males × Fmr1 heterozygous female breeders (for 
experiments involving Fmr1 WT/Grm5 +/+ , Fmr1 WT/Grm5 +/− , Fmr1 KO/Grm5 +/+ 
and Fmr1 KO/Grm5 +/− groups). The number of subjects (n) varies by experiment. For 
the visuospatial discrimination experiments indicated in Fig. 1b,c, the number of subjects 
by group was as follows: Fmr1 WT/Grm5+/+, n=42; Fmr1 WT/Grm5+/−, n = 34; Fmr1 
KO/Grm5+/+, n = 45; Fmr1 KO/Grm5+/−, n = 32. For the experiments indicated in Fig. 
1d,e, the number of subjects by group was as follows: Fmr1 WT/vehicle, n=33; Fmr1 
WT/lova, n=23; Fmr1 KO/vehicle, n = 34; Fmr1 KO/lova, n = 33. For the instrumental 
extinction experiments indicated in Fig. 2, the number of subjects by group was as 
follows: Fmr1 WT, n = 16; Fmr1 KO, n = 16. For the instrumental extinction 
experiments indicated in Fig. 3a,b,e,f, the number of subjects by group was as follows: 
Fmr1 WT/Grm5 +/+ , n = 14; Fmr1 WT/Grm5+/−, n = 15; Fmr1 KO/Grm5+/+, n = 15; 
Fmr1 KO/Grm5+/−, n = 14. For the experiments indicated in Fig. 3c,d,g,h, the number of 
subjects by group was as follows: Fmr1 WT/vehicle, n = 12; Fmr1 WT/lova; n = 10; 
Fmr1 KO/vehicle, n = 11; Fmr1 KO/lova, n = 9. All the experiments were carried out 
blind to genotype using littermate controls, and were conducted during the light phase. 
All procedures were approved by the MIT Committee on Animal Care. 
Behavioral apparatus 
All the experiments were carried out using operant conditioning chambers (Med 
Associates, St. Albans, VT, USA) which had five nose-poke apertures on one wall of the 
chamber and a pellet dispenser and magazine for delivering food rewards (20mg dustless 
precision pellets, BioServ, Frenchtown, NJ, USA) on the opposite wall. A house light 
over the food magazine permanently illuminated the chamber. Stimulus lights inside the 
nose-poke apertures could be controlled individually to provide visual cues during 
acquisition and extinction, as noted. 
Food restriction 
In all the experiments, daily food restriction began after P60. During food restriction, the 
body weight of subjects was maintained at 85 – 90% free-feeding weight by providing 
unrestricted access to food for 1.5 – 2 h/day immediately following daily experimental 
testing. Mice did not have access to food for the rest of the day. The duration and time of 
feeding were kept consistent within each cohort to avoid motivation becoming a 
confounding variable. In some cases (where noted), experiments were conducted only 5 
or 6 days/week. In these cases, ad libitum access to food was allowed on non-
experimental days. 
Acquisition of a five-choice visuospatial discrimination 
Our five-choice visuospatial discrimination task was based on Krueger et al. (2011). All 
training sessions lasted 15 min. Magazine training: Subjects were placed in the 
behavioral apparatus and each entry into the food magazine was reinforced by one food 
pellet on a fixed-time of 10-second schedule. Subjects received two consecutive days of 
magazine training. Phase 1: During phase 1 of acquisition, all five nose-poke apertures 
were illuminated and active. To receive a reward, the subject had to respond in any 
illuminated aperture (‘correct’ response) and then return to the magazine for reward. 
Rewards were delivered on a fixed FR1 schedule. Illumination of apertures temporarily 
ceased during reward delivery until the reward was retrieved. On the first 2days of phase 
1, all mice were ‘primed’ to respond in the apertures by placing a food pellet in each of 
the five apertures before the beginning of the session. In addition, any mouse recording 
less than five correct responses for 2 days in a row would be primed on the following 
day. To reach criterion and advance to the next training phase, mice were required to 
complete 15 trials within the 15-min session on two consecutive days. Phase 2: During 
phase 2, only one aperture was illuminated at random on each trial. To receive a reward, 
the subject had to respond in the illuminated aperture (‘correct’ response) and then return 
to the magazine. ‘Incorrect’ responses were defined as any response into a non-
illuminated aperture and had no programmed consequence. To reach criterion and 
complete the task, mice had to complete 15 or more trials and achieve a 50% or greater 
success rate [defined as correct responses/(correct responses + incorrect responses)] on 
two consecutive days. Mice were excluded if they failed to reach criterion on phase 2 
within 20 days. Experiments were conducted 6 – 7 days/week. All procedures were 
consistent with Krueger et al. (2011). 
Acquisition and extinction of an instrumental response 
Three of the five nose-poke apertures (the outer two apertures and the center aperture) 
were closed using metal plugs (Med Associates), leaving only two open. Magazine 
training: Two days of magazine training occurred as described above. Acquisition: One 
of the two apertures was illuminated, and food rewards were delivered via the magazine 
following a correct response. Illumination of apertures temporarily ceased during reward 
delivery. The same aperture was illuminated on each trial within a session and between 
sessions over days. Half of subjects had the left aperture illuminated and half had the 
right aperture illuminated. To encourage responding, rewards were delivered on a fixed 
FR1 schedule for the first 10 rewards, then on a variable VR2 schedule (randomly 
requiring either 1, 2 or 3 responses) for the following rewards. To reach criterion and 
advance to extinction training, mice were required to complete 15 trials with a >75% 
success rate on five consecutive days. Extinction: For three to five consecutive days 
following acquisition, extinction sessions were conducted in which no rewards were 
delivered following a response in either aperture. Groups: Fmr1 KO/WT cohorts were 
trained 7 days/week. Fmr1 KO/Grm5+/− and Fmr1 KO ± lovastatin cohorts were trained 
5 days/week. Extinction training was always conducted on three consecutive days 
following at least two consecutive days of acquisition. Therefore subjects in Fmr1 
KO/Grm5+/− and Fmr1 KO ± lovastatin cohorts were trained to criterion for a range of 
5–9days to enable three consecutive extinction days following the final two acquisition 
days. 
Lovastatin treatment 
Lovastatin or vehicle was formulated in the food at a dose of 10 mg/kg/day, as reported 
(Osterweil et al. 2013; Yamada et al. 2000). ‘Lovachow’ was administered for 1 month 
prior to the beginning of experiments, from P30 to P60. During experiments, lovachow 
was used for the 1.5to 2-h unrestricted feeding. Lovastatin or vehicle was not present in 
reward pellets. 
Statistical analysis 
Where noted, extinction data (plotted as correct responses or incorrect responses) were 
normalized within animal to the last 5 days of acquisition averaged together. Two-way 
analysis of variance (ANOVA) was used to analyze five-choice and two-choice 
acquisition data where a 2 × 2 experimental design was used (Fmr1 genotype × Grm5 
genotype and Fmr1 genotype × lovastatin treatment). Student’s t-test was used to 
compare two-choice acquisition where two experimental groups were used (Fmr1 KO 
and WT). To analyze extinction data, either a two-factor or a three-factor repeated 
measures ANOVA was used. The repeated measure was days of extinction, one factor 
was Fmr1 genotype, and where applicable, the other factor was either Grm5 genotype or 
lovastatin treatment. Student’s t-test or two-way ANOVA was used to compare raw 
baseline responding between groups. Post hoc Bonferroni tests were used. Outliers >2 
SDs from the mean were excluded. N represents number of animals and error bars are 
±SEM. 
Results 
Impaired visuospatial discrimination in Fmr1 KO mice is not significantly reversed 
by partial reduction of mGluR5 signaling  
Fmr1 KO mice show deficits in a visuospatial discrimination task, which are consistent 
with impairments in cognitive flexibility (Krueger et al. 2011). In this assay, mice are 
placed in an operant conditioning chamber with five nose-poke apertures and a food 
magazine (Fig. 1a). Mice are trained on a visuospatial discrimination in two phases. In 
phase 1, all nose-poke apertures are illuminated and a response in any illuminated 
aperture results in reward delivery. In phase 2, only one aperture is randomly illuminated, 
and only a response in this aperture results in food reward. A previous study indicated 
that acquisition of phase 2, but not phase 1, is delayed in Fmr1 KO mice, indicating that 
these mice may be impaired in the ability to flexibly respond to changing reward 
contingencies (Krueger et al. 2011). Based on previous success in improving other Fmr1 
KO phenotypes, we asked whether two interventions could correct this cognitive 
phenotype: (1) genetic cross with Grm5+/− mice (heterozygous for deletion of mGluR5) 
and (2) chronic administration of lovastatin for 4weeks prior to testing, which has been 
shown to modestly reduce ERK1/2 signaling. We quantified the number of training days 
required to reach criterion for each phase (15 correct trials on two consecutive days for 
phase 1 and 15 correct trials on two consecutive days with over 50% correct for phase 2, 
see Materials and methods). 
Genetic cross of Fmr1+/− females and Grm5+/− males produced male offspring of four 
experimental genotypes: Fmr1 WT/Grm5+/+, Fmr1 KO/Grm5+/+, Fmr1 WT/Grm5+/− 
and Fmr1 KO/Grm5+/−. There was no effect of Fmr1 genotype or Grm5 genotype on 
phase 1 acquisition in this group (Fig. 1b; n=32–45; two-way ANOVA: main effect of 
Fmr1 genotype, F 1,133 = 1.634, P = 0.203; main effect of Gmr5 genotype, F 1,133 < 1; 
Fmr1 × Grm5 interaction, F 1,133 < 1). We saw a trend suggesting an effect of Fmr1 
genotype on phase 2 acquisition, but this did not reach statistical significance (Fig. 1c; 
two-way ANOVA: main effect of Fmr1 genotype, F 1,149 = 3.591, P = 0.060). There 
was no significant interaction between Fmr1 and Grm5 genotype (F 1,149 = 1.678, P = 
0.197). 
Figure 1: Visuospatial discrimination in Fmr1 KO mice is not significantly impacted by partial reduction of 
mGluR5 signaling. (a) Schematic showing timing of treatment strategies relative to food restriction and two 
phases of training on a five-choice visuospatial discrimination task. (b) Phase 1 acquisition is normal in 
Fmr1/Grm5 cross. (c) There is a trend toward delayed acquisition of phase 2 as a function of Fmr1 
genotype (# P = 0.06, n = 32 – 45). There is not a statistically significant interaction between Fmr1 and 
Grm5 genotypes (WT/Grm5 +/+ : 8.4 ± 0.5 days to acquisition; KO/Grm5 +/+ : 10.6 ± 0.7 days; KO/Grm5 
+/− : 8.9 ± 0.7 days). (d) In cohorts treated chronically with lovachow or similarly formulated vehicle 
chow, Fmr1 KO mice show impaired phase 1 acquisition (WT/vehicle: 8.3 ± 0.4 days; KO/vehicle: 10.4 ± 
0.5 days, ***P < 0.001), which is not observed following lovastatin treatment (KO/lova: 9.3 ± 0.3 days, *P 
< 0.05). (e) Lovachow/vehicle cohorts show no effect of genotype or drug treatment on phase 2 acquisition. 
Lovastatin, an indirect downregulator of ERK1/2 signaling, has been shown to correct 
audiogenic seizures as well as altered synaptic plasticity and excitability in Fmr1 KO 
mice (Osterweil et al. 2013). Chronic lovastatin dosing in food (‘lovachow’) also corrects 
seizures in Fmr1 KO mice, but this approach has not yet been tested on cognitive deficits. 
Animals were tested in the visuospatial discrimination task following 4 weeks of 
lovachow or vehicle and concurrent with active dosing (Fig. 1a). Fmr1 KO mice 
surprisingly showed a delay in phase 1 operant acquisition not previously reported (Fig. 
1d; n = 24 – 38; two-way ANOVA: main effect of Fmr1 genotype, F 1,131 = 6.889, P = 
0.010). This delay in days to criterion was not observed following chronic lovastatin 
dosing (genotype × drug interaction, F 1,131 = 4.990, P = 0.027). Post hoc analysis 
showed significant differences between WT/vehicle and KO/vehicle groups (P < 0.001), 
as well as KO/vehicle and KO/lovachow groups (P < 0.05). There was no concurrent 
delay in phase 2 acquisition in Fmr1 KO mice and no effect of lovastatin (Fig. 1e; two-
way ANOVA: main effect of genotype, F 1,119 < 1; main effect of drug treatment, F 
1,119 < 1; genotype×treatment interaction, F1,119 <1). 
Instrumental extinction is exaggerated in Fmr1 KO mice  
Although there was no statistically significant effect of the Grm5+/− genotype in the 
visuospatial discrimination task, we observed an interesting trend that might indicate an 
amelioration of cognitive function by mGluR5 reduction. To further investigate this 
possibility, we decided to expand our analysis of phenotypes related to PFC function in 
the Fmr1 KO mice. Due to previous reports of altered extinction of a fear response 
(Dolen et al. 2007), we tested whether extinction of an appetitive operant response is also 
altered in Fmr1 KO mice (2a; n = 16/group). In this experiment, mice were first trained 
on a two-choice instrumental response, in which one aperture was illuminated and active, 
whereas the other was not illuminated and inactive. Acquisition of this task was normal 
in Fmr1 KO mice, as measured by days to criterion (Fig. 2b; Student’s t-test, P = 0.657). 
In addition, absolute performance during the final 5 days of acquisition was similar 
between WT and Fmr1 KO mice [Fig. 2c; Student’s t-test, P = 0.906, Fig. 2d; Student’s t-
test on ‘ACQ (acquisition)’, P = 0.456]. Subsequently, mice received extinction training, 
during which no reward was delivered following a response in the illuminated or non-
illuminated aperture. Surprisingly, we found that Fmr1 KO mice displayed exaggerated 
extinction learning (Fig. 2d; repeated measures two-way ANOVA, main effect of 
genotype, F 1,30 = 12.679, P = 0.001; genotype × day interaction, F 4,120 = 8.080, P = 
0.001; post hoc tests: D1, P=0.001, D2, P=0.034, D3, P=0.023, D4, P=0.020, D5, P = 
0.625). We normalized correct responses during extinction by animal to the last 5 days of 
acquisition to account for individual differences in basal response rate and found similar 
results (Fig. 2e; repeated measures two-way ANOVA: main effect of genotype, F 1,30 = 
7.906, P = 0.009; genotype/day interaction, F 4,120 = 5.982, P = 0.004; post hoc tests: 
D1, P =0.005; D2, P =0.071; D3, P =0.093; D4, P =0.053; repeated measures two-way 
ANOVAs, main effect of day, F 4,120 = 9.822, P < 0.001 for raw data; F 4,120 = 5.513, 
P < 0.001 for normalized data). There was no significant effect of genotype (F 1,30 = 
1.815, P = 0.188 raw and F 1,30 < 1 normalized) and no interaction between genotype 
and day (F4,120=1.551, P=0.204 raw and F4,120=1.277, P=0.150 normalized). However, 
as we observed a trend toward a decrease in incorrect responses, we calculated the 
percentage of correct responses [defined as number of correct responses/(number of 
correct + incorrect responses) × 100] to determine the effect of changes in total 
responses. There was no significant effect of genotype on percentage of correct responses 
(Fig. 2h,i; repeated measures two-way ANOVAs, F 1,30 < 1 raw and F 1,30 < 1 
normalized) or interaction between genotype and test day (F4,120=1.563, P=0.211 raw; F 
4,120 = 1.489, P = 0.230 normalized), indicating that Fmr1 KO mice responded less 
equally at both apertures. 
 
Figure 2: Instrumental extinction is exaggerated in Fmr1 KO mice. (a) Schematic shows a test with one 
acquisition phase, followed by 5 days of extinction. (b) Days to acquisition and (c) performance during 
acquisition are normal in Fmr1 KO mice. (d) Extinction of correct responding is significantly exaggerated 
in Fmr1 KO mice (***P = 0.001, repeated measures two-way ANOVA) and post hoc tests show significant 
exaggeration at days 1 – 4 (*P < 0.05). (e) Normalization shows significantly exaggerated extinction in 
Fmr1 KO mice (***P = 0.001), and post hoc tests show a significant exaggeration at day 1 (**P < 0.01). 
There is no effect of Fmr1 genotype on incorrect responses (f,g) or on the rate of correct responses (h,i). 
Partial inhibition of mGluR5 signaling fails to improve exaggerated instrumental 
extinction in Fmr1 KO mice  
We next tested whether 50% genetic reduction of mGluR5 or chronic lovastatin would 
correct exaggerated instrumental extinction in Fmr1 KO mice. There was no effect of 
Fmr1 genotype on acquisition in either the Fmr1/Grm5 cross (Fig. 3a; two-way ANOVA: 
main effect of Fmr1 genotype, F 1,53 = 3.248, P = 0.077; Fig. 3b; two-way ANOVA: 
main effect of Fmr1 genotype, F 1,53 < 1) or the Fmr1 ± lovastatin groups (Fig. 3c; two-
way ANOVA: main effect of Fmr1 genotype, F 1,37 = 1.029, P = 0.317; Fig. 3d; two-
way ANOVA: main effect of Fmr1 genotype, F 1,37 < 1). Chronic lovastatin treatment 
did improve acquisition, independent of genotype (Fig. 3c; two-way ANOVA, main 
effect of drug, F 1,37 = 10.065, P = 0.003, but no genotype × drug interaction, F 1,37 = 
2.298, P = 0.138). 
During extinction training, Fmr1/Grm5 cross cohorts (n = 14 – 15) showed a significant 
reduction in responding at the correct aperture independent of genotype (Fig. 3e; repeated 
measures three-way ANOVA: main effect of day, F 2,100 = 108.429, P < 0.001), but 
there was no main effect of either Fmr1 or Grm5 genotype (F 1,50 < 1), no Fmr1/Grm5 
interaction (F 1,10 = 3.119, P = 0.084) and no Fmr1/Grm5 /day interaction (F2,100 <1). 
Interestingly, there was a significant effect of Fmr1 genotype on responding at the 
incorrect aperture (Fig. 3f; repeated measures three-way ANOVA, main effect of Fmr1 
genotype, F 1,50 = 7.440, P = 0.009), but no correction by Grm5 cross (Fmr1 × Grm5 
interaction, F 1,50 < 1, Fmr1 × Grm5 × day interaction, F 1,50 < 1). There was no 
difference in basal response rates during acquisition between genotypes (two-way 
ANOVA: main effect of Fmr1 genotype, F 1,57 < 1; main effect of Grm5 genotype, F 
1,57 < 1; Fmr1 × Grm5 interaction, F 1,57 < 1). 
During extinction training, lovastatin or vehicle-treated cohorts (n = 9 – 12) showed a 
significant reduction in responding at the correct aperture independent of drug treatment, 
and this was significantly exaggerated in Fmr1 KO mice (Fig. 3g; repeated measures 
three-way ANOVA: main effect of Fmr1 genotype, F 1,37 = 10.175, P = 0.003). Chronic 
lovastatin treatment does not correct exaggerated extinction (main effect of drug, F 1,37 
< 1; genotype × drug interaction, F 1,37 < 1; no significant drug × day or genotype × 
drug × day interactions). No significant effect of Fmr1 genotype on responding at the 
incorrect aperture was observed (Fig. 3d; three-way repeated measures ANOVA: main 
effect of Fmr1 genotype, F 1,37 < 1). However, lovastatin did alter responding at the 
incorrect aperture, independent of genotype (F 1,37 = 5.885, P = 0.020). There was no 
significant genotype × treatment, genotype × day, treatment × day or genotype × 
treatment × day interaction. There was no difference in basal response rates during 
acquisition between genotypes (two-way ANOVA: main effect of Fmr1 genotype, F 1,38 
= 3.484, P = 0.070; main effect of Gmr5 genotype, F 1,38 < 1; Fmr1 × Grm5 interaction, 
F 1,38 < 1). 
Figure 3: Inhibition of mGluR5 and ERK signaling pathways is insufficient to correct exaggerated 
instrumental extinction in Fmr1 KO mice. (a) Days to acquisition and (b) performance during acquisition 
are normal in Fmr1 KO mice in Fmr1/Grm5 cross groups. (c) In lovastatinor vehicle-treated groups, days to 
acquisition is normal in Fmr1 KO mice, but there is a significant improvement in performance with 
lovastatin treatment, independent of genotype (‡‡ P < 0.01). (d) In lovastatinor vehicle-treated groups, 
performance during acquisition is normal in Fmr1 KO mice. (e) In Fmr1/Grm5 cross cohorts, there is no 
significant effect of Fmr1 genotype on extinction, and no Fmr1/Grm5 interaction. (f) Effect of Fmr1 
genotype on incorrect responding (**P < 0.01). (g) Extinction of an instrumental response is significant 
exaggerated in Fmr1 KO mice independent of lovachow treatment (**P < 0.01). (h) Effect of lovachow 
treatment on incorrect responding (‡ P < 0.05). There is no effect of Fmr1 genotype and no genotype × 
drug interaction. 
Discussion 
Development of reliable and robust assays to model high-level cognitive deficits in FX 
and other disorders could provide a valuable system to test the efficacy of 
pharmacological treatments in mice. Here, we describe a novel form of instrumental 
extinction learning that is altered in Fmr1 KO mice in parallel with visuospatial 
discrimination (Krueger et al. 2011). 
Fmr1 KO mice display exaggerated instrumental extinction (Fig. 2), while at the same 
time showing impaired visuospatial discrimination. A key element of impaired 
visuospatial discrimination in Fmr1 KO mice is that it is accompanied by perseverative 
behavior and a lack of cognitive flexibility (Kramvis et al. 2013; Krueger et al. 2011). 
Cognitive inflexibility – the inability to modify behavior with changing rules – has been 
reported in many human neuropsychiatric disorders and mouse models and involves 
dopaminergic signaling in both PFC and striatum (Klanker et al. 2013). 
Extinction of a learned instrumental behavior is different from switching rules (i.e. 
between acquisition phases 1 and 2), and thus it is not entirely surprising that extinction is 
exaggerated while visuospatial discrimination is impaired. 
Exaggerated extinction of inhibitory avoidance, a learning paradigm whose acquisition is 
hippocampally encoded, has been previously reported in Fmr1 KO mice (Dolen et al. 
2007). In PFC, extinction of operant drug-seeking behavior is regulated by mGlu5. 
Specifically, positive allosteric modulation of mGlu5 results in exaggerated extinction for 
multiple reinforcers, and mGlu5 KO mice have delayed extinction (Chesworth et al. 
2013; Cleva et al. 2011; Gass & Olive 2009; Kufahl et al. 2012). Assuming that food and 
drug rewards have similar saliency and involve similar circuits, our results would be 
consistent with enhanced mGlu5 signaling. In Fmr1 KO mice, levels of mGlu5 protein 
are normal. However, in the absenceofthetranslationalrepressorFMRP,proteinsynthesis 
downstream of mGlu5 is enhanced in Fmr1 KO mice. Extracellular signal-regulated 
kinase signaling, linking mGlu5 to protein synthesis, is also upregulated in the cortex of 
Fmr1 KO mice (Michalon et al. 2012). It is therefore a reasonable hypothesis that 
upregulation of pathways downstream of mGlu5 may account for exaggerated 
instrumental extinction in Fmr1 KO mice. It has previously been shown that a reduction 
in mGlu5 signaling can correct a wide range of behavioral phenotypes in the Fmr1 KO 
mice, including cognitive phenotypes (De Vrij et al. 2008; Dolen et al. 2007; Levenga et 
al. 2011; Michalon et al. 2012; Vinueza Veloz et al. 2012; Yan et al. 2005). In this study, 
neither the 50% reduction in mGluR5 expression nor chronic treatment with lovastatin 
was sufficient to correct altered extinction in Fmr1 KO mice (Fig. 3). However, a trend 
toward improvement in visuospatial discrimination was seen in the Fmr1 KO/Grm5+/− 
cross (Fig. 1c). It is possible that additional improvements could be observed by adjusting 
dosages. Our choices here were guided by success in previous studies using other FX 
phenotypes (Dolen et al. 2007; Osterweil et al. 2013). 
One aim of our study was to assess whether instrumental extinction and visuospatial 
discrimination are robust assays of PFC-mediated cognitive dysfunction in Fmr1 KO 
mice that can be reliably used to test potential therapeutic agents. In this context, it is 
important to note that the impairment observed in the visuospatial discrimination assay 
appears to be sensitive to environmental conditions, as the Fmr1 KO phenotype observed 
in the Grm5 cross experiment (Fig. 1b,c) is different from that observed in the lovastatin 
experiment (Fig. 1d,e). In the Grm5 cross experiment, we saw a trend toward delayed 
phase 2 acquisition in Fmr1 KO mice (P = 0.06) as reported previously (Krueger et al. 
2011). If Grm5 had not been tested cross concurrently, the difference between Fmr1 KO 
and WT mice would have been statistically significant. However, in the lovastatin 
experiment, we saw no phase 2 phenotype but did see a surprising phase 1 delay which 
has not been previously reported. As mice in the latter cohorts were raised on a different 
dietary formulation (BioServ, for both vehicle and lovachow), it is possible that this 
formulation altered either metabolism or the saliency of the reward (a different type of 
food pellet), and therefore motivation, in these cohorts. It has also been shown that 
dietary conditions may influence learning and memory performance in mice (Yu et al. 
2010). Our data indicate that the instrumental extinction phenotype may be less sensitive 
to these influences and hence more suitable for the study of pharmacological 
interventions. 
It is interesting that an improvement in operant acquisition was observed following 
lovastatin treatment, which was independent of Fmr1 genotype (Fig. 3). These results 
represent unexpected effects of lovastatin on operant acquisition and deserve further 
study. 
Ultimately, developing robust assays for altered cognition is worthwhile in Fmr1 KO 
mice as cognitive impairments are at the core of FX. Different mechanisms are likely to 
underlie separate cognitive tasks such as the visuospatial discrimination and extinction of 
instrumental responses, and it is therefore not surprising that treatment strategies vary in 
their effectiveness depending on the cognitive test. This is an important point to consider 
in designing clinical trials where properly defined endpoints are crucial. It is imperative 
to understand which cognitive behaviors may be most amenable to treatment by which 
drugs. The ability to measure multiple Fmr1 KO phenotypes under similar conditions 
could be useful for therapeutic drug screens, the results of which may provide insights 
into the proper endpoints to be considered for clinical trials in FX and other 
neurodevelopmental disorders associated with intellectual disability. 
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